Sumithra J Mandrekar

发表

Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials

Fangrong Yan, Sumithra J Mandrekar, Ying Yuan, 2017, Clinical Cancer Research.

Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials

Bradley P Carlin, Brian P Hobbs, Daniel J Sargent, 2011, Biometrics.

Multipopulation Tailoring Clinical Trials: Design, Analysis, and Inference Considerations

Alex Dmitrienko, Sumithra J Mandrekar, Brian A Millen, 2014, Therapeutic innovation & regulatory science.

Time to progression ratio: promising new metric or just another metric?

Sumithra J Mandrekar, Ming-Wen An, 2016, Annals of translational medicine.

An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles

Daniel J Sargent, Jun Yin, Sumithra J Mandrekar, 2018, Journal of biopharmaceutical statistics.

Modeling of Heart Period Data And A Study of the Associated Spectral Measures

Sumithra J Mandrekar, 2002 .

Improving Clinical Trial Efficiency: Thinking outside the Box.

Richard Simon, Sumithra J Mandrekar, Suzanne E Dahlberg, 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Predictive biomarker validation in practice: lessons from real trials

Daniel J Sargent, Sumithra J Mandrekar, D. Sargent, 2010, Clinical trials.

Definitions and statistical properties of master protocols for personalized medicine in oncology

Sumithra J Mandrekar, Lindsay A Renfro, S. Mandrekar, 2018, Journal of biopharmaceutical statistics.

Are our data symmetric?

Sumithra J Mandrekar, Jayawant N Mandrekar, 2003, Statistical methods in medical research.

Precision oncology: A new era of cancer clinical trials.

Sumithra J Mandrekar, Lindsay A Renfro, Ming-Wen An, 2017, Cancer letters.

Model‐based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challenges

Daniel J Sargent, Rui Qin, Sumithra J Mandrekar, 2010, Statistics in medicine.

Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All

Daniel J Sargent, Sumithra J Mandrekar, D. Sargent, 2009, Journal of biopharmaceutical statistics.

An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations

Daniel J Sargent, Sumithra J Mandrekar, Yue Cui, 2007, Statistics in medicine.

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

Daniel J Sargent, Sumithra J Mandrekar, D. Sargent, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trials: time for a new era in clinical trial design.

Daniel J Sargent, Sumithra J Mandrekar, D. Sargent, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers

Daniel J Sargent, Sumithra J Mandrekar, D. Sargent, 2013, Clinical trials.

Statistical modelling of the differences between successive R–R intervals

Sumithra J Mandrekar, Gary G Berntson, H. Nagaraja, 2005, Statistics in medicine.

Evaluation of Glutathione Metabolic Genes on Outcomes in Advanced Non-small Cell Lung Cancer Patients after Initial Treatment with Platinum-Based Chemotherapy: An NCCTG-97-24-51 Based Study

Zhifu Sun, Sumithra J Mandrekar, Ping Yang, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I Trial of Sirolimus Combined with Radiation and Cisplatin in Non-small Cell Lung Cancer

Sumithra J Mandrekar, Steven E Schild, Jann N Sarkaria, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CT screening for lung cancer: five-year prospective experience.

Anne-Marie Sykes, Sumithra J Mandrekar, S. Swensen, 2005, Radiology.

Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668

Rui Qin, Brent A Bauer, Sumithra J Mandrekar, 2011, Cancer Prevention Research.

Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: results from the ACOSOG Z4032 (Alliance) multicenter randomized trial.

Dwight E Heron, Sumithra J Mandrekar, D. Heron, 2015, The Journal of thoracic and cardiovascular surgery.

A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032).

Dwight E Heron, David R Jones, David R. Jones, 2016, The Annals of thoracic surgery.

Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities

Rui Qin, Sarah Zohar, Sumithra J Mandrekar, 2013, Statistics in medicine.